Press Releases
Press Releases
- ConjuChem Announces Fiscal 2010 Second Quarter Financial Results
- CONJUCHEM'S CREDITORS APPROVE PLAN OF REORGANIZATION AND COMPROMISE
- CONJUCHEM ANNOUNCES PROPOSED PLAN OF REORGANISATION AND COMPROMISE
- CONJUCHEM NOT TO FILE INTERIM FINANCIAL STATEMENTS
- CONJUCHEM RETAINS BLOOM BURTON & CO.
- ConjuChem Files for Restructuring
- ConjuChem Biotechnologies Announces Fiscal 2009 Year-End Financial Results
- ConjunChem to Evaluate Strategic Alternatives
- ConjuChem Announces U.S. Patent & Trademark office issues final office action rejection all claims in Amylin Patent
- ConjuChem Announces Fiscal 2009 Third Quarter Financial Results
- CONJUCHEM ANNOUNCES COMPLETION OF $5 MILLION NON-DILUTIVE CAPITAL TRANSACTION
- CONJUCHEM ANNOUNCES SECURITYHOLDER APPROVAL FOR THE $5 MILLION NON-DILUTIVE FINANCING
- CONJUCHEM ANNOUNCES COURT DATE FOR FINAL ORDER OF THE $5 MILLION NON-DILUTIVE FINANCING
-
Management Information Circular
In connection with an arrangement involving ConjuChem Biotechnologies and Colabor Income Fund
Special Meeting of Shareholders
August 17, 2009 Click here for download - CONJUCHEM RAISES $5 MILLION IN NON-DILUTIVE FINANCING
- Conjuchem Announces Fiscal 2009 Second Quarter Financials Results
- CONJUCHEM REPORTS DATA ON PC-DAC™:EXENDIN-4 AND PC-INSULIN AT 2009 AMERICAN DIABETES ASSOCIATION MEETING
- ConjuChem Announces Management Change
- ConjuChem Announces Fiscal 2009 First Quarter Financial Results
- ConjuChem Announces U.S. Patent & Trademark Office Rejects All Claims In Amylin Patent And Issues Action Closing Prosecution
- ConjuChem Reports Final Data Confirming PC-DAC™: Exendin-4 Lowers Glucose and Weight in Phase II Diabetes Trials
- ConjuChem Biotechnologies Announces Fiscal 2008 Year-End Financial Results
- ConjuChem's PC-DAC™: Exendin-4 Lowers Glucose and Weight in Phase II Diabetes Trials
- ConjuChem and Novozymes Enters Long-Term Supply Agreement for Recombumin® use in PC:DAC™:Exendin-4
- ConjuChem Provides Development Update
- ConjuChem Announces Fiscal 2008 Third Quarter Financial Results
- ConjuChem Announces Fiscal 2008 Second Quarter Financial Results
- ConjuChem Announces Changes to the Board of Directors
- ConjuChem Announces Fiscal 2008 First Quarter Financial Results
- ConjuChem Initiates Phase II Study of PC-DAC™:Exendin-4
- ConjuChem Biotechnologies Announces Fiscal 2007 Year-End Financial Results
- Conjuchem Biotechnologies Inc. Completes $22 Million Bought Deal Financing
- ConjuChem Biotechnologies Inc. Announces $22 Million Bought Deal Financing
- ConjuChem Reports Final Results of PC-DAC™: Exendin-4 Phase I/II Multiple-Dose Study for Type 2 Diabetes Confirming Safety and Efficacy at Once-Weekly Dosing
- Conjuchem's Request For Patent Reexamination Is Granted By U.S. Patent & Trademark Office
- ConjuChem Biotechnologies Announces Fiscal 2007 Third Quarter Financial Results
- Conjuchem Appoints Vice President & General Counsel
- Conjuchem Biotechnologies Announces Filing Of Patent Reexamination Request In U.S. Patent & Trademark Office
- ConjuChem Biotechnologies Reports PC-DAC™: Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
- ConjuChem Biotechnologies Announces Fiscal 2007 Second Quarter Financial Results
- PC-DAC™:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
- ConjuChem Biotechnologies Announces Fiscal 2006 Year-End Financial Results
- CONJUCHEM BIOTECHNOLOGIES INC. COMPLETES $120.25 MILLION FINANCING
- CONJUCHEM BIOTECHNOLOGIES INC. ANNOUNCES FILING OF FINAL PROSPECTUS
- CONJUCHEM BIOTECHNOLOGIES INC. ANNOUNCES FINANCING
- New Study of PC-DAC™Exendin-4 for Type 2 Diabetes Confirms Excellent Tolerability, Efficacy, and Extended Duration of Activity
- ConjuChem Initiates Phase I/II Multiple-Dose Study of PC-DAC™:Exendin-4
- CONJUCHEM BIOTECHNOLOGIES ANNOUNCES FISCAL 2006 THIRD QUARTER FINANCIAL RESULTS
- Final Results of PC-DAC™:Exendin-4 Phase I/II Trial for Type 2 Diabetes Confirm Excellent Tolerability, Positive Efficacy, and Extended Duration of Activity - New Three-Week Study Also Announced -
- CONJUCHEM PROVIDES FINDINGS OF DAC™:GRF HIV LIPODYSTROPHY TRIAL INVESTIGATION
- ConjuChem Announces Clinical Hold of its DAC™:GRF Program in HIV Lipodystrophy
- Presentations of ConjuChem's Novel Growth Hormone Therapeutic Highlighted at the 88th Annual Meeting Of The Endocrine Society
- ConjuChem Successfully Completes Patient Enrollment of its Phase II Trial of DAC™:GRF for Treatment of HIV Lipodystrophy
- ConjuChem Biotechnologies Inc. Announces Fiscal 2006 Second Quarter Financial Results for Conjuchem Inc.
- ConjuChem's PC- DAC™:Exendin-4 Presented at the American Diabetes Association Annual Meeting
- ConjuChem Announces New Executive Vice President, Research and Development
- CONJUCHEM COMPLETES CORPORATE REORGANIZATION
ConjuChem Receives $6.4 million in Non-Dilutive Capital - ConjuChem Completes $15.75 Million Financing
- ConjuChem Announces $15.75 Million Bought Deal of Common Shares
- Phase I/II Preliminary Results of PC-DAC™: Exendin-4 Trial for Type 2 Diabetes Demonstrate Excellent Tolerability and Positive Efficacy
- ConjuChem Announces Fiscal 2006 First Quarter Financial Results
- ConjuChem to Initiate Phase I/II Clinical Study of PC-DAC™: Exendin-4 for Type 2 Diabetes
- ConjuChem Announces Reorganization and Non-Dilutive Funding
- ConjuChem Announces Fiscal 2005 Year-End Financial Results
- ConjuChem's PC-DAC(TM):Exendin-4 Advancing into Human Clinical Testing For Type 2 Diabetes
- ConjuChem Announces New President and CEO
- ConjuChem Provides Clinical Update on DAC™:GLP-1 Program and PC-Dac™:Exendin-4
- ConjuChem Announces Fiscal 2005 Third Quarter Financial Results
- CONJUCHEM DEVELOPS NEW PLATFORM, PC-DAC™
© 1999-2007, ConjuChem, Inc. All rights reserved.
